These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26379170)

  • 1. Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials.
    Dodge HH; Zhu J; Mattek NC; Austin D; Kornfeld J; Kaye JA
    PLoS One; 2015; 10(9):e0138095. PubMed ID: 26379170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimizing the Sample Sizes of Clinical Trials on Preclinical and Early Symptomatic Stage of Alzheimer Disease.
    Luo J; Weng H; Morris JC; Xiong C
    J Prev Alzheimers Dis; 2018; 5(2):110-119. PubMed ID: 29616704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Digital Cognitive Biomarkers for Alzheimer's Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline.
    Bock JR; Hara J; Fortier D; Lee MD; Petersen RC; Shankle WR
    J Prev Alzheimers Dis; 2021; 8(2):123-126. PubMed ID: 33569557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment.
    Insel PS; Donohue MC; Mackin RS; Aisen PS; Hansson O; Weiner MW; Mattsson N;
    Neurobiol Aging; 2016 Dec; 48():172-181. PubMed ID: 27710807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
    Caroli A; Prestia A; Wade S; Chen K; Ayutyanont N; Landau SM; Madison CM; Haense C; Herholz K; Reiman EM; Jagust WJ; Frisoni GB;
    Alzheimer Dis Assoc Disord; 2015; 29(2):101-9. PubMed ID: 25437302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.
    Chen K; Roontiva A; Thiyyagura P; Lee W; Liu X; Ayutyanont N; Protas H; Luo JL; Bauer R; Reschke C; Bandy D; Koeppe RA; Fleisher AS; Caselli RJ; Landau S; Jagust WJ; Weiner MW; Reiman EM;
    J Nucl Med; 2015 Apr; 56(4):560-6. PubMed ID: 25745091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and sample size considerations for Alzheimer's disease prevention trials using multistate models.
    Brookmeyer R; Abdalla N
    Clin Trials; 2019 Apr; 16(2):111-119. PubMed ID: 30922116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years.
    Albert M; Zhu Y; Moghekar A; Mori S; Miller MI; Soldan A; Pettigrew C; Selnes O; Li S; Wang MC
    Brain; 2018 Mar; 141(3):877-887. PubMed ID: 29365053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment.
    Guercio BJ; Donovan NJ; Munro CE; Aghjayan SL; Wigman SE; Locascio JJ; Amariglio RE; Rentz DM; Johnson KA; Sperling RA; Marshall GA
    J Alzheimers Dis; 2015; 47(2):421-32. PubMed ID: 26401564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
    Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
    Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passive Assessment of Routine Driving with Unobtrusive Sensors: A New Approach for Identifying and Monitoring Functional Level in Normal Aging and Mild Cognitive Impairment.
    Seelye A; Mattek N; Sharma N; Witter P; Brenner A; Wild K; Dodge H; Kaye J
    J Alzheimers Dis; 2017; 59(4):1427-1437. PubMed ID: 28731434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining clinically meaningful decline in preclinical Alzheimer disease.
    Insel PS; Weiner M; Mackin RS; Mormino E; Lim YY; Stomrud E; Palmqvist S; Masters CL; Maruff PT; Hansson O; Mattsson N
    Neurology; 2019 Jul; 93(4):e322-e333. PubMed ID: 31289148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.